Understand the source comparison
Best Peptides to Improve Brain Function Ranked: Performance Comparison
The table below ranks peptides by mechanism, primary cognitive domain affected, bioavailability, and evidence quality. Ranking is based on the strength of mechanistic data (receptor-level evidence), replicability across independent research groups, and applica
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below ranks peptides by mechanism, primary cognitive domain affected, bioavailability, and evidence quality. Ranking is based on the strength of mechanistic data (receptor-level evidence), replicability across independent research groups, and applicability to cognitive enhancement rather than disease-state intervention.
- Dihexa
- HGF/c-Met potentiation → dendritic spine proliferation
- Spatial memory, learning acquisition
- Oral: 60–70% bioavailability
- Strong preclinical (rodent models), no Phase 3 human trials
- Strongest mechanistic case for memory consolidation; oral route is unique among peptide nootropics; lacks large-scale human data
- Cerebrolysin
- Exogenous neurotrophic factor delivery (BDNF, NGF, CNTF mimetics)
- Neuroprotection, post-injury recovery
- IV or IM only; no oral activity
- Strong clinical evidence in stroke/TBI populations; weaker in healthy subjects
- Best-supported neuroprotective peptide; limited evidence for cognitive enhancement in non-injured populations
- P21
- CREB pathway activation → synaptic protein synthesis
- Long-term memory consolidation, recognition memory
- Intranasal or SubQ; no oral bioavailability
- Moderate preclinical evidence; no human trials published
- CREB-targeted nootropic with documented LTP enhancement; entirely preclinical at this stage
- Semax
- ACTH(4-10) analogue → BDNF upregulation and monoamine modulation
- Attention, focus, stress resilience
- Intranasal: moderate bioavailability
- Moderate preclinical + small human trials (Russian literature)
- Dopaminergic and serotonergic modulation with secondary BDNF effects; human data limited to Eastern European studies
- NA-Selanc
- Tyr-Lys-Met-Glu-His-Phe-Pro-Gly-Pro sequence → GABAergic modulation
- Anxiety reduction, stress-induced cognitive impairment
- Intranasal; bioavailability unknown
- Weak preclinical evidence; minimal replication
- Anxiolytic with secondary nootropic claims; mechanism poorly characterised compared to direct neuroplasticity modulators